Concomitant autoimmune diseases in patients with anti-phospholipid syndrome: a cohort study in Sweden

OBJECTIVE: Our objective was to assess the prevalence and incidence of autoimmune diseases (ADs) in a cohort of patients with anti-phospholipid syndrome (APS) in Stockholm Region, compared with the general population. The impact of a high-risk anti-phospholipid antibody profile, defined as triple positivity, was examined. METHOD: In this retrospective cohort study, 250 patients with APS followed at Karolinska University Hospital, Stockholm, from 2014 to 2020 were included through medical record review. ADs were classified as rheumatic (RADs) or non-rheumatic (NRADs) using ICD-10 codes. Logistic regression was used to estimate adjusted odds ratios (aORs) for ADs associated with patient characteristics at the start of follow-up. Population comparators (5:1 ratio) were matched by birth year, sex, and area of residence. Incidence rate ratios (IRRs) were estimated by Poisson regression with 95% confidence intervals (CIs). RESULTS: Among the cohort (68% women, median age 45 years, interquartile range 35-59 years), 127 patients had ADs at the start of follow-up. The prevalence of AD was 51%; 96 (38%) had a RAD and 55 (22%) an NRAD. Triple positivity was present in 48% of patients and was associated with increased odds of AD (aOR1.6, 95% CI 0.95-2.6). During follow-up, all patients with APS had a significantly higher incidence of new ADs compared with population comparators (IRR 7.5, 95% CI 4.4-13.0). There was a high incidence of new ADs in triple-positive patients (IRR 8.3, 95% CI 4.1-16.7). CONCLUSION: Patients with APS, particularly those with triple-positive antibodies, exhibit high autoimmune comorbidity, supporting the need for careful longitudinal follow-up.

Authors

Institutions

Publication Details

Journal
Scandinavian Journal of Rheumatology
Published
2026-11-18
DOI
https://doi.org/10.1080/03009742.2026.2722819
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Concomitant autoimmune diseases in patients with anti-phospholipid syndrome: a cohort study in Sweden

Aleksandra Antovič, E. Svenungsson, Natali Karandyszowska, H Alagunduz et al.
Scandinavian Journal of Rheumatology
Systemic Lupus Erythematosus Research
article

Concomitant autoimmune diseases in patients with anti-phospholipid syndrome: a cohort study in Sweden

Aleksandra Antovič, E. Svenungsson, Natali Karandyszowska, H Alagunduz, M Bruzelius, A Dominicus, J Colic, EV Arkema, J Widaeus
article en

Abstract

OBJECTIVE: Our objective was to assess the prevalence and incidence of autoimmune diseases (ADs) in a cohort of patients with anti-phospholipid syndrome (APS) in Stockholm Region, compared with the general population. The impact of a high-risk anti-phospholipid antibody profile, defined as triple positivity, was examined. METHOD: In this retrospective cohort study, 250 patients with APS followed at Karolinska University Hospital, Stockholm, from 2014 to 2020 were included through medical record review. ADs were classified as rheumatic (RADs) or non-rheumatic (NRADs) using ICD-10 codes. Logistic regression was used to estimate adjusted odds ratios (aORs) for ADs associated with patient characteristics at the start of follow-up. Population comparators (5:1 ratio) were matched by birth year, sex, and area of residence. Incidence rate ratios (IRRs) were estimated by Poisson regression with 95% confidence intervals (CIs). RESULTS: Among the cohort (68% women, median age 45 years, interquartile range 35-59 years), 127 patients had ADs at the start of follow-up. The prevalence of AD was 51%; 96 (38%) had a RAD and 55 (22%) an NRAD. Triple positivity was present in 48% of patients and was associated with increased odds of AD (aOR1.6, 95% CI 0.95-2.6). During follow-up, all patients with APS had a significantly higher incidence of new ADs compared with population comparators (IRR 7.5, 95% CI 4.4-13.0). There was a high incidence of new ADs in triple-positive patients (IRR 8.3, 95% CI 4.1-16.7). CONCLUSION: Patients with APS, particularly those with triple-positive antibodies, exhibit high autoimmune comorbidity, supporting the need for careful longitudinal follow-up.

Scandinavian Journal of Rheumatology
Karolinska University Hospital (SE), Danderyds sjukhus (SE), Karolinska Institutet (SE), University of Belgrade (RS)
Stiftelsen Konung Gustaf V:s 80-årsfond, Reumatikerförbundet
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon